The U.S. Food and Drug Administration announced it is proposing to remove oral phenylephrine as an active ingredient that can be used in over-the-counter (OTC) monograph ...
demonstrated a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to placebo. WAYPOINT is a randomized, double-blind trial ...
Oral phenylephrine, a common nasal-congestion ingredient in over-the-counter drugs, shouldn't be used in monograph drug products, the Food and Drug Administration is proposing. The agency said a ...